Company Overview of Ceregene, Inc.
Ceregene, Inc. develops treatment of neurodegenerative disorders using the delivery of nervous system growth factors. Its therapeutic programs include CERE-110, an AAV vector delivery system that is in a Phase II clinical trial for the treatment of Alzheimer’s disease. The company was incorporated in 2000 and is based in San Diego, California. As of October 1, 2013, Ceregene, Inc. operates as a subsidiary of Sangamo Biosciences Inc.
9381 Judicial Drive
San Diego, CA 92121
Founded in 2000
Key Executives for Ceregene, Inc.
Chief Scientific Officer and Executive Vice President
Senior Director of Human Resources and Administration
Compensation as of Fiscal Year 2014.
Ceregene, Inc. Key Developments
Ceregene, Inc. Auditor Raises 'Going Concern' Doubt
Dec 9 13
Ceregene, Inc. filed its 8-K/A on Dec 09, 2013 for the period ending Dec 31, 2012. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Ceregene, Inc., Sangamo Biosciences Inc. - M&A Call
Aug 26 13
To discuss the acquisition and provide a general business overview
Ceregene, Inc. Reports Data from Parkinson's Disease Phase 2b Study
Apr 19 13
Ceregene, Inc. announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120, a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease. The trial did not demonstrate statistically significant efficacy on the primary endpoint. However, one of the key secondary endpoints, as defined and prespecified in the Statistical Analysis Plan, did produce statistically significant benefit. The trial also provided further evidence for the safety of CERE-120 and the dosing methods employed. A marked placebo effect was observed in this trial in that both the sham-surgery-control patients and the CERE-120 treated patients showed significant improvement following their surgery. Fifty-one patients with moderately advanced Parkinson's disease who could not be satisfactorily controlled with conventional Parkinson's medication were enrolled in the study at 11 leading clinical sites throughout the U.S. Approximately half of the patients received CERE-120 while the other half received sham (placebo) surgery as a control. Patients were monitored for 15-24 months to assess safety and changes in Parkinson's disease symptoms, using multiple endpoints such as the Unified Parkinson's Disease Rating Scale, Daily Diaries that assess motor function throughout the day, and PDQ-39, among others. Ceregene continues to analyze the data from this trial to gain as much information as possible.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|